{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:06:23Z","timestamp":1784934383869,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vascular Pharmacology"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1016\/j.vph.2020.106682","type":"journal-article","created":{"date-parts":[[2020,5,11]],"date-time":"2020-05-11T00:14:51Z","timestamp":1589156091000},"page":"106682","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation"],"prefix":"10.1016","volume":"130","author":[{"given":"G.","family":"Camporese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Bernardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.P.","family":"Avruscio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Marchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bonfante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Furian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Neri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Villalta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Fabris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.T.","family":"Sartori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vph.2020.106682_bb0005","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1016\/j.transproceed.2013.07.017","article-title":"Incidence of late deep venous thrombosis among renal transplant patients","volume":"45","author":"Todeschini","year":"2013","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.vph.2020.106682_bb0010","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/ndt\/12.1.167","article-title":"Environmental and genetic determinants of the hypercoagulable state and cardiovascular disease in renal transplant recipients","volume":"12","author":"Irish","year":"1997","journal-title":"Nephrol. Dial. Transplant."},{"key":"10.1016\/j.vph.2020.106682_bb0015","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/ki.2013.536","article-title":"The risk of thromboembolic events in kidney transplant patients","volume":"85","author":"Verhave","year":"2014","journal-title":"Kidney Int."},{"key":"10.1016\/j.vph.2020.106682_bb0020","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00007890-199801270-00015","article-title":"Venous thromboembolic complications after kidney and kidney-pancreas transplantation: a multivariate analysis","volume":"65","author":"Humar","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.vph.2020.106682_bb0025","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1538-7836.2006.01917.x","article-title":"Renal transplant recipients are at high risk for both symptomatic and asymptomatic deep-vein thrombosis","volume":"4","author":"Poli","year":"2006","journal-title":"J. Thromb. Haemost."},{"issue":"10","key":"10.1016\/j.vph.2020.106682_bb0030","doi-asserted-by":"crossref","DOI":"10.3390\/jcm7100370","article-title":"Epidemiology and prognostic importance of atrial fibrillation in kidney transplant recipients: a meta-analysis","volume":"7","author":"Thongprayoon","year":"2018","journal-title":"J Clin Med"},{"issue":"2","key":"10.1016\/j.vph.2020.106682_bb0035","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.chest.2015.11.026","article-title":"Antithrombotic therapy for venous thromboembolism disease. CHEST guideline and expert panel report","volume":"149","author":"Kearon","year":"2016","journal-title":"Chest"},{"key":"10.1016\/j.vph.2020.106682_bb0040","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur. Heart J."},{"issue":"5","key":"10.1016\/j.vph.2020.106682_bb0045","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation. CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.vph.2020.106682_bb0050","author":"Bayer"},{"key":"10.1016\/j.vph.2020.106682_bb0055","author":"Janssen Pharmaceuticals Inc."},{"key":"10.1016\/j.vph.2020.106682_bb0060","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.thromres.2013.07.004","article-title":"Treatment with everolimus is associated with a procoagulant state","volume":"132","author":"Baas","year":"2013","journal-title":"Thromb. Res."},{"key":"10.1016\/j.vph.2020.106682_bb0065","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1097\/00007890-199212000-00007","article-title":"Impaired fibrinolysis in cyclosporine-treated renal transplant patients. Analysis of the defect and beneficial effect of fish-oil","volume":"54","author":"Levi","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.vph.2020.106682_bb0070","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1097\/00007890-199505270-00010","article-title":"Reduced fibrinolytic potential one year after kidney transplantation. Relationship to long-term steroid treatment","volume":"59","author":"Patrassi","year":"1995","journal-title":"Transplantation"},{"key":"10.1016\/j.vph.2020.106682_bb0075","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1111\/cts.12580","article-title":"Drug-drug interaction study on apixaban with cyclosporine and tacrolimus in healthy volunteers","volume":"11","author":"Bashir","year":"2018","journal-title":"Clin Transl Sci"},{"issue":"2","key":"10.1016\/j.vph.2020.106682_bb0080","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1097\/TP.0000000000000223","article-title":"Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A","volume":"98","author":"Wannhoff","year":"2014","journal-title":"Transplantation"},{"issue":"1","key":"10.1016\/j.vph.2020.106682_bb0085","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/FTD.0000000000000356","article-title":"Effect of the direct oral anticoagulants rivaroxaban and apixaban on the disposition of calcineurin inhibitors in transplant recipients","volume":"39","author":"Vanhove","year":"2017","journal-title":"Ther Drug Moni"},{"key":"10.1016\/j.vph.2020.106682_bb0090","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1177\/1526924816661951","article-title":"Evaluation of direct oral anticoagulation therapy in heart and lung transplant recipients","volume":"26","author":"Lichvar","year":"2016","journal-title":"Prog. Transplant."},{"key":"10.1016\/j.vph.2020.106682_bb0095","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1136\/postgradmedj-2013-132474","article-title":"Direct oral anticoagulants: integration into clinical practice","volume":"90","author":"Cowell","year":"2014","journal-title":"Postgrad. Med. J."},{"key":"10.1016\/j.vph.2020.106682_bb0100","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.vph.2020.106682_bb0105","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.12873","article-title":"Direct oral anticoagulant considerations in solid organ transplantation: a review","volume":"31","author":"Salerno","year":"2017","journal-title":"Clin. Transpl."},{"key":"10.1016\/j.vph.2020.106682_bb0110","unstructured":"Lexicomp Online\u00ae, Lexi-Drugs\u00ae, Hudson, OH: Lexi-Comp, Inc.; 2016."},{"key":"10.1016\/j.vph.2020.106682_bb0115","author":"Micromedex 2.0.Greenwood Village, CO: Truven Health Analytics, Inc."},{"key":"10.1016\/j.vph.2020.106682_bb0120","unstructured":"Clinical Pharmacology [databaseonline] Tampa, FL; Gold Standard, Inc.; 2016. www.clinicalpharmacology.com. Accessed June 2, 2016."},{"issue":"20","key":"10.1016\/j.vph.2020.106682_bb0125","doi-asserted-by":"crossref","first-page":"4032","DOI":"10.1182\/blood-2012-12-453076","article-title":"The laboratory and the direct oral anticoagulants.","volume":"121","author":"Tripodi","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.vph.2020.106682_bb0130","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/asheducation-2014.1.329","article-title":"Monitoring target-specific oral anticoagulants","volume":"2014","author":"Konkle","year":"2014","journal-title":"Hematology Am Soc Hematol Educ Program."},{"key":"10.1016\/j.vph.2020.106682_bb0135","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3109\/10408368909106595","article-title":"Generation and application of data on biological variation in clinical chemistry","volume":"27","author":"Fraser","year":"1989","journal-title":"Crit. Rev. Clin. Lab. Sci."},{"key":"10.1016\/j.vph.2020.106682_bb0140","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1093\/clinchem\/20.12.1535","article-title":"Effects of intra- and interindividual variation on the appropriate use of normal ranges","volume":"20","author":"Harris","year":"1974","journal-title":"Clin. Chem."}],"container-title":["Vascular Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189119301922?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1537189119301922?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T01:18:34Z","timestamp":1761527914000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1537189119301922"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7]]},"references-count":28,"alternative-id":["S1537189119301922"],"URL":"https:\/\/doi.org\/10.1016\/j.vph.2020.106682","relation":{},"ISSN":["1537-1891"],"issn-type":[{"value":"1537-1891","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Absence of interaction between rivaroxaban, tacrolimus and everolimus in renal transplant recipients with deep vein thrombosis or atrial fibrillation","name":"articletitle","label":"Article Title"},{"value":"Vascular Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vph.2020.106682","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"106682"}}